Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH) consisting of the full 44-amino acid GHRH sequence with a trans-3-hexenoic acid group added to the N-terminus for stability. It is the only GHRH analog to have achieved FDA approval — specifically for HIV-associated lipodystrophy (reduction of excess visceral abdominal fat in HIV-infected adults) — providing a well-characterized clinical safety and efficacy profile that makes it a valuable research reference compound.
Tesamorelin stimulates pituitary somatotrophs via the GHRH receptor to increase endogenous GH secretion in a pulsatile pattern. Unlike exogenous GH administration, this preserves the natural feedback regulation of the GH axis. The FDA-approved clinical indication specifically targets visceral adipose tissue reduction, reflecting the compound's documented specificity for visceral vs subcutaneous fat in research subjects.
Third-party tested · Lot-specific COA · US domestic shipping 24–48h
Buy Tesamorelin Now →| Purity | ≥99% (HPLC verified, third-party) |
| Molecular Weight | 5,135.9 Da |
| Appearance | White to off-white lyophilized powder |
| Storage | –20°C long-term; 4°C up to 14 days after reconstitution |
| Lot Number | OL-2026-007 |
| Format | Lyophilized powder, sealed vial |
| Certificate of Analysis | Lot-specific COA included with every order |
| Intended Use | In vitro laboratory research only |
| Regulatory Status | FDA-approved reference compound (Egrifta® for HIV lipodystrophy) |
Research Use Disclaimer: Tesamorelin is sold strictly for in vitro laboratory research purposes only. Not for human consumption, veterinary use, or clinical application. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.